苏州复融生物技术

Furon Biotechnology is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery and development of innovative protein therapeutics. The company utilizes its proprietary F-mP (Furon-modified Protein) technology platform to perform site-specific modifications, significantly improving the pharmacokinetic and pharmacodynamic profiles of protein drugs. Furon's primary research focus lies in the field of synthetic biology, specifically targeting cytokines for oncology and autoimmune diseases. Its lead candidate, FR001, is a next-generation IL-2 analog currently undergoing clinical evaluation for the treatment of advanced solid tumors. By optimizing the therapeutic window of potent biological molecules, Furon aims to provide safer and more effective treatment options for patients worldwide.